Literature DB >> 23700289

Cardiorenal syndrome: pathophysiology and treatment.

Dmitry Shchekochikhin1, Robert W Schrier, JoAnn Lindenfeld.   

Abstract

CRS is a common problem in patients with advanced heart failure. Arterial underfilling with consequent neurohormonal activation, systemic and intrarenal vasoconstriction, and salt and water retention cause the main clinical features of CRS which include a progressive decline in renal function, worsening renal function during treatment of heart failure (HF) decompensation and resistance to loop diuretics. Impaired renal function in HF patients often reflects more advanced stages of cardiac failure, and thus is associated with a worse prognosis. However, a transient fall in glomerular filtration rate may be a result of successful treatment of congestion, and thereby might not be associated with decreased survival in HF patients. This review covers basic pathophysiological mechanisms underlying the CRS and current trends in practical approaches to treat these patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23700289     DOI: 10.1007/s11886-013-0380-4

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  64 in total

Review 1.  Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization.

Authors:  Parag Jain; Barry M Massie; Wendy A Gattis; Livin Klein; Mihai Gheorghiade
Journal:  Am Heart J       Date:  2003-02       Impact factor: 4.749

2.  Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure.

Authors:  Daniel E Forman; Javed Butler; Yongfei Wang; William T Abraham; Christopher M O'Connor; Stephen S Gottlieb; Evan Loh; Barry M Massie; Michael W Rich; Lynne Warner Stevenson; James B Young; Harlan M Krumholz
Journal:  J Am Coll Cardiol       Date:  2004-01-07       Impact factor: 24.094

Review 3.  Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death.

Authors:  Jan O Friedrich; Neill Adhikari; Margaret S Herridge; Joseph Beyene
Journal:  Ann Intern Med       Date:  2005-04-05       Impact factor: 25.391

4.  Diuretic strategies in patients with acute decompensated heart failure.

Authors:  G Michael Felker; Kerry L Lee; David A Bull; Margaret M Redfield; Lynne W Stevenson; Steven R Goldsmith; Martin M LeWinter; Anita Deswal; Jean L Rouleau; Elizabeth O Ofili; Kevin J Anstrom; Adrian F Hernandez; Steven E McNulty; Eric J Velazquez; Abdallah G Kfoury; Horng H Chen; Michael M Givertz; Marc J Semigran; Bradley A Bart; Alice M Mascette; Eugene Braunwald; Christopher M O'Connor
Journal:  N Engl J Med       Date:  2011-03-03       Impact factor: 91.245

5.  Effects of ULTRAfiltration vs. DIureticS on clinical, biohumoral and haemodynamic variables in patients with deCOmpensated heart failure: the ULTRADISCO study.

Authors:  Cristina Giglioli; Daniele Landi; Emanuele Cecchi; Marco Chiostri; Gian Franco Gensini; Serafina Valente; Mauro Ciaccheri; Gabriele Castelli; Salvatore Mario Romano
Journal:  Eur J Heart Fail       Date:  2010-12-03       Impact factor: 15.534

6.  Relation of worsened renal function during hospitalization for heart failure to long-term outcomes and rehospitalization.

Authors:  David E Lanfear; Edward L Peterson; Janis Campbell; Hemant Phatak; David Wu; Karen Wells; John A Spertus; L Keoki Williams
Journal:  Am J Cardiol       Date:  2011-01       Impact factor: 2.778

Review 7.  Cardiorenal syndrome in acute decompensated heart failure.

Authors:  Mohammad Sarraf; Amirali Masoumi; Robert W Schrier
Journal:  Clin J Am Soc Nephrol       Date:  2009-11-19       Impact factor: 8.237

Review 8.  Acute decompensated heart failure and the cardiorenal syndrome.

Authors:  Kelly V Liang; Amy W Williams; Eddie L Greene; Margaret M Redfield
Journal:  Crit Care Med       Date:  2008-01       Impact factor: 7.598

9.  The mechanism of decrease in dynamic mitral regurgitation during heart failure treatment: importance of reduction in the regurgitant orifice size.

Authors:  L B Rosario; L W Stevenson; S D Solomon; R T Lee; S C Reimold
Journal:  J Am Coll Cardiol       Date:  1998-12       Impact factor: 24.094

10.  Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF).

Authors:  Liviu Klein; Barry M Massie; Jeffrey D Leimberger; Christopher M O'Connor; Ileana L Piña; Kirkwood F Adams; Robert M Califf; Mihai Gheorghiade
Journal:  Circ Heart Fail       Date:  2008-05       Impact factor: 8.790

View more
  3 in total

Review 1.  The acute cardiorenal syndrome: burden and mechanisms of disease.

Authors:  Petra Nijst; Wilfried Mullens
Journal:  Curr Heart Fail Rep       Date:  2014-12

2.  Continuous versus intermittent use of furosemide in patients with heart failure and moderate chronic renal dysfunction.

Authors:  Zhigui Zheng; Xinxin Jiang; Jianguo Chen; Dongyuan He; Xiaohui Xie; Yunan Lu
Journal:  ESC Heart Fail       Date:  2021-03-10

3.  Olmesartan medoxomil reverses glomerulosclerosis in renal tissue induced by myocardial infarction without changes in renal function.

Authors:  Xiao-Mei Lu; Yu-Nan Jin; Ling Ma
Journal:  Exp Ther Med       Date:  2014-04-25       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.